CHANGING PATTERN OF RELAPSE IN OSTEOSARCOMA OF THE EXTREMITIES TREATED WITH ADJUVANT AND NEOADJUVANT CHEMOTHERAPY

被引:26
作者
BACCI, G
RUGGIERI, P
PICCI, P
BRICCOLI, A
FERRARO, A
FERRARI, S
TIENGHI, A
IANTORNO, D
CAMPANACCI, M
机构
[1] Department of Chemotherapy, Bologna
[2] First Department of Orthopaedics, Bologna
[3] Bone Tumor Center of the Istituto Ortopedico Rizzoli, Bologna
[4] Department of Surgery, University of Modena, Ravenna
[5] Department of Medical Oncology, Santa Maria delle Croci Hospital, Ravenna
关键词
OSTEOSARCOMA; ADJUVANT CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; RELAPSE;
D O I
10.1179/joc.1995.7.3.230
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In 551 patients with osteosarcoma of the extremities treated between 1980 and 1991 in our Institution with surgery only (35 cases), surgery combined with adjuvant chemotherapy (147 cases) or neoadjuvant chemotherapy (363 cases) the relapse patterns were analyzed. Adjuvant chemotherapy was performed according to 2 different protocols and neoadjuvant chemotherapy according to 3 different protocols successively activated. In the 252 patients who relapsed, the interval between initial treatment and first relapse was significantly longer in the group treated with adjuvant and neoadjuvant chemotherapy (18.1 and 21.3 mo) than in the group treated with surgery only (5.4 mo). For patients treated with neoadjuvant chemotherapy, a longer interval was seen in the most effective regimen of neoadjuvant chemotherapy (25 mo). No significant differences were seen among the 3 groups, according to the site of first metastasis, although in patients treated with the most effective neoadjuvant regimen there was a higher incidence of bone metastasis. In patients who relapsed with pulmonary metastases the average number of nodules seen by standard X-rays, as well as CT scans, was significantly higher in patients treated with surgery only (3.6) than in patients treated with adjuvant or neoadjuvant chemotherapy (2.5 and 2.6 nodules). We conclude that these changes in metastatic pattern in patients treated with adjuvant and neoadjuvant chemotherapy are important, because they may encourage the use of salvage therapy with thoracotomy in a larger number of patients. Prolongation of time relapsed after more effective regimens of adjuvant and neoadjuvant chemotherapy should be considered when evaluating the preliminary results of new chemotherapy protocols.
引用
收藏
页码:230 / 239
页数:10
相关论文
共 34 条
[1]  
Avella M., Bacci G., Campanacci M., T rattamento dell’os- teosarcoma non-metastatico delle estremita: L’esperienza recente (1972-1982) dell’istituto Ortopedico Rizzoli in 290 pazienti trattati con la sola chirurgia od associando alla chirurgia la chemioterapia complementare, Minerva Ort Traumat, 39, pp. 431-441, (1988)
[2]  
Bacci G., Gherlinzoni F., Picci P., Et al., Adriamycin- methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: A randomized study, Eur J Cancer Clin Oncol, 22, pp. 1337-1344, (1986)
[3]  
Benjamin R.S., Chawla S.P., Carrasco C., Et al., Arterial Infusion in the Treatment of Osteosarcoma. In, pp. 269-274, (1988)
[4]  
Bramwell V.H., Burgers M., Sneath R., Et al., A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup, J Clin Oncol, 10, pp. 1579-1591, (1992)
[5]  
Cortes E.P., Holland J.F., Wang J.J., Et al., Amputation and adriamycin in primary osteosarcoma, N Engl J Med, 291, pp. 998-1000, (1974)
[6]  
Eilber F., Giuliano A., Eckardt J., Patterson K., Moseley S., Goodnight J., Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial, J Clin Oncol, 5, pp. 21-26, (1987)
[7]  
Gorin A.M., Perez-Atayde A., Gebhardt M., Et al., Weekly high-dose methotrexate and doxorubicin for osteosarcoma: The Dana-Farber Cancer Institute/The Children Hospital - Study III, J Clin Oncol, 5, pp. 1178-1184, (1987)
[8]  
Jaffe N., Smith D., Jaffe M.R., Et al., Intraarterial cisplatin in the management of Stage IIB osteosarcoma in the pediatric and adolescent age group, Clin Orthop Rel Res, 270, (1991)
[9]  
Meyers P.A., Heller G., Healey et al. Chemotherapy for non-metastatic osteogenic sarcoma: The Memorial Sloan- Kettering Experience, J Clin Oncol, 10, pp. 5-15, (1992)
[10]  
Miser J., Krailo M., Osteosarcoma: The Childrens Cancer Group (CCG) Studies, Osteosarcoma in Adolescents and Young Adults, pp. 287-291, (1993)